HK Stock Market Move | TRANSTHERA-B(02617) soared over 50% and broke through the ceiling. In less than three months, the stock price has skyrocketed 21 times, with a total market value exceeding 110 billion Hong Kong dollars.

TRANSTHERA-B (02617) surged by more than 50%. The stock was listed on June 23, and in less than three months, the current stock price has soared 21 times from the offer price of HK$13.15. As of the time of writing, it has increased by 49.09%, reaching HK$287, with a turnover of HK$21.99 billion and a total market value exceeding HK$110 billion. On the news front, the Shanghai Stock Exchange and the Shenzhen Stock Exchange recently announced that Pharmaron Health was included in the list of Hong Kong Stock Connect securities, effective from September 8. On September 10, Pharmaron Health announced that its core product, Tenzipflorfenie combined with fluorsilicide for the treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative or low expression (HER2-) recurrent or metastatic breast cancer II clinical trial that failed treatment, has obtained clinical implied approval from the National Medical Products Administration on September 10, 2025. It is worth noting that according to the prospectus, Pharmaron Health's founder, Wu Yongqian, holds a stake of 32.98%, combined with other institutional holdings, resulting in limited market float. From the trading data, as of the time of writing, the stock has a high volatility of 71% and a turnover rate of only 3.14%. In addition, the company's interim performance shows that in the first half of this year, it did not generate revenue from its main business, and other income and gains decreased from HK$10.4 million in the first half of 2024 to HK$3.6 million, a decrease of 65.1%; it recorded a pre-tax loss of HK$123 million in the first half of the year, an improvement from the loss of HK$160 million in the same period of 2024.